Compass Pathways shares rise ahead of FDA psilocybin hearing
Compass Pathways shares rose Tuesday as investors treated a new commercial-readiness push as a sign the company is preparing to file its psilocybin depression treatment with the FDA. Shares closed up 5% and edged up a further 4%.
Compass Pathways shares rose on Tuesday as investors viewed a new commercial-readiness push as another sign the company is preparing to file its psilocybin depression treatment with the Food and Drug Administration. CMPS shares closed up 5% in the regular trading session and then added a further 4% after that.